PIK3CA

Dec 15, 2020

Roche's Ipatasertib Shows No PFS Benefit in Phase III, Biomarker-Guided TNBC Trial
Premium

Dec 15, 2020

Roche Nabs CE Mark for PIK3CA Test for Breast Cancer

Sep 20, 2020

Advanced Breast Cancer Patients Benefit From Targeted, Conventional Therapy Combo, ESMO Studies Show
Premium

Sep 4, 2020

Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy

Aug 14, 2020

Novartis' Piqray Approved in Canada for PIK3CA-Mutated Advanced Breast Cancer

Jul 31, 2020

European Commission Approves Novartis' Piqray, Fulvestrant for PIK3CA-Mutated Breast Cancer

Jul 7, 2020

Menarini to Launch Trial Evaluating PI3K Inhibitor MEN1611 in Metastatic Colorectal Cancer

Jun 1, 2020

CHMP Recommends Approval of Novartis' Piqray in PIK3CA-Mutated Advanced Breast Cancer

Jun 1, 2020

Novartis' Piqray Effective in Breast Cancer Subset; Bayer's Aliqopa Gives Limited Signals in NCI-MATCH

May 31, 2020

Despite Search, Predictive Biomarkers for Kadcyla in HER2-Positive Breast Cancer Remain Elusive

Apr 15, 2020

Guardant360 Results in Alpelisib Trial Suggest Liquid Biopsy May Help Better Capture Non-Responders
Premium

Apr 1, 2020

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Feb 13, 2020

Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel

Feb 3, 2020

Qiagen Obtains CE Mark for PIK3CA Mutation Assay

Nov 19, 2019

Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds
Premium

May 24, 2019

FDA Approves Novartis' Piqray for PIK3CA-Mutated Advanced Breast Cancer

Dec 7, 2018

Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing
Premium

Oct 30, 2018

Precision Oncology Highlights From ESMO 2018

Jun 3, 2018

ASCO Study Shows Modest Efficacy of PI3 Kinase Inhibitor in Molecularly Defined Breast Cancer
Premium

Jun 3, 2018

NCI-MATCH Researchers Discuss First Data From Three Treatment Arms at ASCO
Premium